From February 28 to March 4, Seegene participated in HPV 2017 (the 31st International Papillomavirus Conference) that was held this year in Cape Town, South Africa, a prominent international conference on the topic of the human papillomavirus (HPV).

A biennial conference, HPV 2017 focuses on diagnostic and prevention techniques for cervical cancer, and introduces the latest trends and treatment methods for HPV testing in each country. At this year’s conference, Seegene introduced two of its major products: the Anyplex™ II HPV28 Detection, which simultaneously identifies 28 genotypes including 19 high-risk and 9 low-risk HPV genotypes known as a cause of cervical cancer, and Anyplex™ II HPV HR Detection, which enables simultaneous screening of 14 high-risk HPVs.

At the symposium held on March 2, Dr. Anja O?trbenk (Ljubljana, Slovenia) presented the clinical validity and accuracy of the test method using Anyplex™ II HPV HR Detection from a VALGENT 3 (Validation of HPV Genotyping Tests) study, which gained significant attention from participants.

VALGENT is a study framework for defining the clinical significance and potential role of HPV screening and genotyping tests, and comparing and evaluating their accuracy by HPV detection products currently used in cervical cancer screenings. Through this year’s conference, Seegene once again proved the clinical validity of its HPV detection product, which was also emphasized as the only product capable of simultaneously screen and identify individual 14 high-risk HPVs by real-time PCR.